Medicl Device Network@2x
Device Development Cardiovascular

Sections

  • Diagnostics
  • Imaging
  • Monitoring
  • Manufacturing
  • Materials
  • Treatments
  • Device Development
    • Anesthesia & Respiratory
    • Cardiovascular
    • Dental
    • Diabetes Care
    • Nephrology & Urology
    • Neurology
    • Opthalmic
    • Orthopedic

Most Read

  • Endospan begins enrolment in TRIOMPHE IDE Study
  • US FDA grants Breakthrough Device Designation to Occlutech’s Atrial Flow Regulator
  • Efemoral Medical initiates study of vascular scaffold system in humans

Most Recent

Device Development

Endospan begins enrolment in TRIOMPHE IDE Study

13 Jan 2021
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Diagnostics
    • Imaging
    • Monitoring
    • Manufacturing
    • Materials
    • Treatments
    • Device Development
      • Anesthesia & Respiratory
      • Cardiovascular
      • Dental
      • Diabetes Care
      • Nephrology & Urology
      • Neurology
      • Opthalmic
      • Orthopedic
  • Deals
  • US Election
  • Disruption
  • Coronavirus
Partners
  • Precision medical wire
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Reports
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Device Development Cardiovascular

Sections

  • Diagnostics
  • Imaging
  • Monitoring
  • Manufacturing
  • Materials
  • Treatments
  • Device Development
    • Anesthesia & Respiratory
    • Cardiovascular
    • Dental
    • Diabetes Care
    • Nephrology & Urology
    • Neurology
    • Opthalmic
    • Orthopedic

Most Read

  • Endospan begins enrolment in TRIOMPHE IDE Study
  • US FDA grants Breakthrough Device Designation to Occlutech’s Atrial Flow Regulator
  • Efemoral Medical initiates study of vascular scaffold system in humans

Most Recent

Device Development

Endospan begins enrolment in TRIOMPHE IDE Study

13 Jan 2021
Latest Cardiovascular
  • Endospan begins enrolment in TRIOMPHE IDE Study
    6 days
  • US FDA grants Breakthrough Device Designation to Occlutech’s Atrial Flow Regulator
    4 weeks
  • Efemoral Medical initiates study of vascular scaffold system in humans
    1 month
  • Gyrus Capital signs deal to acquire LivaNova heart valve business
    2 months
  • Endospan begins enrolment in TRIOMPHE IDE Study
    6 days
  • US FDA grants Breakthrough Device Designation to Occlutech’s Atrial Flow Regulator
    4 weeks
  • Efemoral Medical initiates study of vascular scaffold system in humans
    1 month
  • Gyrus Capital signs deal to acquire LivaNova heart valve business
    2 months
Endospan begins enrolment in TRIOMPHE IDE Study
Device Development

Endospan begins enrolment in TRIOMPHE IDE Study

Israeli company Endospan has announced the first implant of its NEXUS Aortic Arch Stent Graft System on a patient with…

13 Jan 2021

Top 5 Most Read

Analysis 8 hours

Scotland: towards a med tech manufacturing powerhouse

1
Deals Analysis 1 day

Hologic kicks off 2021 with acquisitions in breast cancer market

2
Analysis 4 days

All the feels: advances in measuring human emotion

3
Analysis 5 days

Medical device approvals: FDA takes a STeP in the right direction

4
News 6 days

Valencell blood pressure tech expands to finger and wrist wearables

5

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
medical device

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more